Video

Dr. Epperla on FDA Approval of Frontline Obinutuzumab in Follicular Lymphoma

Author(s):

Narendranath Epperla, MBBS, MS

In Partnership With:

Narendranath Epperla, MBBS, MS, hematologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of frontline obinutuzumab (Gazyva) for the treatment of patients with follicular lymphoma.

Narendranath Epperla, MBBS, MS, hematologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of frontline obinutuzumab (Gazyva) for the treatment of patients with follicular lymphoma.

Related Videos
Michael R. Bishop, MD
Lori A Leslie, MD
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Related Content
Axi-Cel Sustains Long-Term Efficacy in R/R Follicular Lymphoma and MZL
December 10th 2024

Axi-Cel Sustains Long-Term Efficacy in R/R Follicular Lymphoma and MZL

Alice Mims, MD, medical oncologist, associate professor, the Division of Hematology, The Ohio State University Comprehensive Cancer Center—James
February 26th 2024

Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS

Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL
December 10th 2024

Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL

Matthew Lunning, DO, FACP
January 22nd 2024

Lunning and Maddocks Talk Through Frontline MCL Management

Diffuse Large B-cell Lymphoma | Image Credit: © Свет Лана – stock.adobe.com
December 8th 2024

US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL

Diffuse Large B-cell Lymphoma | Image Credit: © LASZLO – stock.adobe.com
December 8th 2024

FS118 Showcases Modest Efficacy in Relapsed/Refractory DLBCL